Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repatha in Critical Limb Ischemia
NCT04306471Phase 4Unknown
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of evolocumab in critical limb ischemia (CLI). Status: unknown.
02
Drugs
evolocumab
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT04306471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306471.